View in EDS

Immunogenicity and Safety of the AS01E-adjuvanted Respiratory Syncytial Virus (RSV) Prefusion F Protein Vaccine in Adults Aged 18–49 Years at Increased Risk of RSV Disease Compared with Adults Aged ≥60 Years.

Saved in:
Bibliographic Details
Title: Immunogenicity and Safety of the AS01E-adjuvanted Respiratory Syncytial Virus (RSV) Prefusion F Protein Vaccine in Adults Aged 18–49 Years at Increased Risk of RSV Disease Compared with Adults Aged ≥60 Years.
Authors: Mitha, Essack1 (AUTHOR), Ferguson, Murdo2 (AUTHOR), Wilhase, Agatha Cathrine3 (AUTHOR), Looze, Ferdinandus De4 (AUTHOR), Vachon, Marie-Louise5 (AUTHOR), Stacey, Helen6 (AUTHOR), Rasalam, Roy7 (AUTHOR), Nozaki, Minoru8 (AUTHOR), Smith, William B9 (AUTHOR), Schwarz, Tino F10 (AUTHOR)
Source: Clinical Infectious Diseases. 5/15/2026, Vol. 82 Issue 5, pe1093-e1103. 11p.
Database: Environment Complete
Description
ISSN:10584838
DOI:10.1093/cid/ciag058